Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.
Wass R, Hochmair M, Kaiser B, Grambozov B, Feurstein P, Weiß G, Moosbrugger R, Sedlmayer F, Lamprecht B, Studnicka M, Zehentmayr F. Wass R, et al. Among authors: studnicka m. Cancers (Basel). 2022 Jun 30;14(13):3226. doi: 10.3390/cancers14133226. Cancers (Basel). 2022. PMID: 35804997 Free PMC article.
[COPD today and in the year 2020].
Lamprecht B, Studnicka M. Lamprecht B, et al. Among authors: studnicka m. Wien Klin Wochenschr. 2007;119(17-18):501-2. doi: 10.1007/s00508-007-0853-9. Wien Klin Wochenschr. 2007. PMID: 17943399 German. No abstract available.
NSCLC: primary tumor size--radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy--first results of a prospective study.
Wurstbauer K, Deutschmann H, Kopp P, Kranzinger M, Merz F, Nairz O, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: studnicka m. Strahlenther Onkol. 2007 Dec;183 Spec No 2:38-40. doi: 10.1007/s00066-007-2015-4. Strahlenther Onkol. 2007. PMID: 18167008 No abstract available.
Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
Wurstbauer K, Deutschmann H, Kopp P, Kranzinger M, Merz F, Nairz O, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: studnicka m. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1345-51. doi: 10.1016/j.ijrobp.2009.06.060. Epub 2009 Nov 10. Int J Radiat Oncol Biol Phys. 2010. PMID: 19910140 Clinical Trial.
163 results